Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
出版年份 2023 全文链接
标题
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
作者
关键词
-
出版物
Clinical Lymphoma Myeloma & Leukemia
Volume 23, Issue 6, Pages 426-437.e11
出版商
Elsevier BV
发表日期
2023-03-18
DOI
10.1016/j.clml.2023.03.005
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021
- (2022) Fabio Efficace et al. Clinical Lymphoma Myeloma & Leukemia
- Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
- (2021) Vania Hungria et al. BRITISH JOURNAL OF HAEMATOLOGY
- Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
- (2021) Torben Plesner et al. BRITISH JOURNAL OF HAEMATOLOGY
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
- (2021) Monia Marchetti et al. Mediterranean Journal of Hematology and Infectious Diseases
- Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
- (2021) Stefan Knop et al. BMC CANCER
- Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
- (2021) Kari Hemminki et al. INTERNATIONAL JOURNAL OF CANCER
- Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial
- (2021) Michael Dolph et al. PHARMACOECONOMICS
- Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies
- (2021) Samer Al Hadidi et al. Blood Advances
- Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
- (2021) Michel Delforge et al. Blood Advances
- Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR
- (2020) Xiaohui Zeng et al. CLINICAL THERAPEUTICS
- Explaining Health State Utility Assessment
- (2020) Eric M. Chang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
- (2020) Heinz Ludwig et al. ONCOLOGIST
- Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
- (2020) Shaji K. Kumar et al. Expert Review of Hematology
- Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: a pharmaco‐economic assessment
- (2020) Carin A. Uyl‐de Groot et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- REAL-WORLD EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA FROM GERMANY
- (2020) Monika Engelhardt et al. Clinical Lymphoma Myeloma & Leukemia
- Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma
- (2020) Albert Oriol et al. LEUKEMIA & LYMPHOMA
- Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
- (2020) Aurore Perrot et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
- (2019) Heinz Ludwig et al. Blood Cancer Journal
- Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells
- (2019) Antonio Olry de Labry Lima et al. BONE MARROW TRANSPLANTATION
- Cost–effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China
- (2019) Jin Lu et al. Journal of Comparative Effectiveness Research
- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
- (2018) Xavier Leleu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) Tian-tian Zhang et al. CLINICAL THERAPEUTICS
- Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
- (2018) Rafat Abonour et al. ANNALS OF HEMATOLOGY
- Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France
- (2018) Nicolas Despiégel et al. Clinical Lymphoma Myeloma & Leukemia
- Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
- (2017) Andrzej J. Jakubowiak et al. Expert Review of Hematology
- The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
- (2016) Christina Ramsenthaler et al. BMC CANCER
- The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials
- (2016) Don Robinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
- (2016) A. Keith Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
- (2016) Andrzej J. Jakubowiak et al. JOURNAL OF MEDICAL ECONOMICS
- Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
- (2015) Sixten Borg et al. ACTA ONCOLOGICA
- Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
- (2015) Katja Weisel et al. Clinical Lymphoma Myeloma & Leukemia
- Health-related quality of life in patients with multiple myeloma - does it matter?
- (2015) A. K. Kvam et al. HAEMATOLOGICA
- Health-related quality of life in patients with multiple myeloma - does it matter?
- (2015) A. K. Kvam et al. HAEMATOLOGICA
- Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
- (2015) S. Z. Usmani et al. JOURNAL OF MEDICAL ECONOMICS
- COMPARATIVE COST-EFFECTIVENESS MODELS FOR THE TREATMENT OF MULTIPLE MYELOMA
- (2014) Keith Cooper et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents
- (2013) P Sonneveld et al. LEUKEMIA
- Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
- (2013) Meletios A. Dimopoulos et al. LEUKEMIA & LYMPHOMA
- Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma
- (2012) T. E. Delea et al. Current Oncology
- Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
- (2012) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey
- (2012) S. Acaster et al. SUPPORTIVE CARE IN CANCER
- Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective
- (2012) Thomas E. Delea et al. JOURNAL OF MEDICAL ECONOMICS
- Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
- (2011) Silvia G. R. Verelst et al. ANNALS OF HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More